A 17-year retrospective study of institutional results for eye plaque brachytherapy of uveal melanoma using 125I, 103Pd, and 131Cs and historical perspective

Brachytherapy

Volumn 10, Issue 4, 2011, Pages 331-339

  Leonard, Kara L ^a   Gagne, Nolan L ^a   Mignano, John E ^a   Duker, Jay S ^a   Bannon, Elizabeth A ^a   Rivard, Mark J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

103Pd; 125I; 131Cs; Brachytherapy; Eye plaque; Uveal melanoma

Indexed keywords

CESIUM 131; IODINE 125; PALLADIUM 103;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CATARACT; ENUCLEATION; EYE PROTECTION; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PLAQUE BRACHYTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RETROSPECTIVE STUDY; TRANSPUPILLARY THERMOTHERAPY; TREATMENT FAILURE; UVEA MELANOMA; VISION; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CESIUM RADIOISOTOPES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PALLADIUM; RADIOISOTOPES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UVEAL NEOPLASMS;

EID: 79958847472     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.01.006     Document Type: Article

References (40)

1. Design and methods of a clinical trial for a rare condition: The Collaborative Ocular Melanoma Study. COMS Report No. 3. Control Clin Trials 1993, 14:362-391. Collaborative Ocular Melanoma Study Group.
2. Jampol L.M., Moy C.S., Murray T.G., et al. The COMS randomized trial of iodine-125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy: COMS Report No. 19. Ophthalmology 2002, 109:2197-2206.
3. Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine-125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS Report No. 27. Ophthalmology 2007, 114:1363-1371. Collaborative Ocular Melanoma Study Group.
4. Quality of life after iodine-125 brachytherapy vs. enucleation for choroidal melanoma: 5-Year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. Arch Ophthalmol 2006, 124:226-238. Collaborative Ocular Melanoma Study-Quality of Life Study Group.
5. The COMS randomized trial of iodine-125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS Report No. 28. Arch Ophthalmol 2006, 124:1684-1693. Collaborative Ocular Melanoma Study Group.
6. Correa R., Pera J., Gomez J., et al. 125I episcleral plaque brachytherapy in the treatment of choroidal melanoma: A single-institution experience in Spain. Brachytherapy 2009, 8:290-296.
7. El-Ghamry M.N., Nag S., Sezginis A., et al. Results of primary treatment of small or medium sized uveal melanoma with custom-made Nag iodine-125 eye plaque: The Ohio State University experience with 119 patients. Brachytherapy 2006, 5:90. (Abstr.).
8. Jensen A.W., Petersen I.A., Kline R.W., et al. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys 2005, 63:101-108.
9. Lumbroso-Le Rouic L., Charif Chefchaouni M., Levy C., et al. 125I plaque brachytherapy for anterior uveal melanomas. Eye 2004, 18:911-916.
10. Nag S., Wang W., Wu H., et al. Custom-made " Nag" eye plaques for 125I brachytherapy. Int J Radiat Oncol Biol Phys 2003, 56:1373-1380.
11. Jones R., Gore E., Mieler W., et al. Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: Dose and dose rate effects. Int J Radiat Oncol Biol Phys 2002, 52:989-995.
12. Quivey J.M., Augsburger J., Snelling L., et al. 125I plaque therapy for uveal melanoma: Analysis of the impact of time and dose factors on local control. Cancer 1996, 77:2356-2362.
13. Fontanesi J., Meyer D., Shizhao X., et al. Treatment of choroidal melanoma with I-125 plaque. Int J Radiat Oncol Biol Phys 1993, 26:619-623.
14. Quivey J.M., Char D.H., Phillips T.L., et al. High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys 1993, 26:613-618.
15. Packer S., Stoller S., Lesser M.L., et al. Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology 1992, 99:767-773.
16. Petrovich Z., Astrahan M.A., Luxton G., et al. Episcleral plaque thermoradiotherapy in patients with choroidal melanoma. Int J Radiat Oncol Biol Phys 1992, 23:599-603.
17. Char D.H., Kroll S., Phillips T.L., et al. Late radiation failures after iodine 25 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology 2002, 109:1850-1854.
18. Finger P.T., Reddy S., Chin K. High-frequency ultrasound characteristics of 24 iris and iridociliary melanomas. Arch Ophthalmol 2007, 125:1051-1058.
19. Finger P.T., Chin K.J., Duvall B.S., et al. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 Treated patients. Ophthalmology 2009, 116:790-796.
20. Finger P.T., Berson A.M., Ng T., et al. Palladium-103 plaque radiation therapy for choroidal melanoma: An 11-year study. Int J Radiat Oncol Biol Phys 2002, 54:1438-1445.
21. Finger P.T. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol 2000, 84:1068-1070.
22. DePotter P., Shields C.L., Shields J.A., et al. Plaque radiotherapy for juxtapapillary choroidal melanoma. Arch Ophthalmol 1996, 114:1357-1365.
23. Lean E.K., Cohen D.M., Liggett P.E., et al. Episcleral radioactive plaque therapy: Initial clinical experience with 56 patients. Am J Clin Oncol 1990, 13:185-190.
24. Shields C.L., Naseripour M., Cater J., et al. Plaque radiotherapy for large posterior uveal melanomas (>8 mm thick) in 354 consecutive patients. Ophthalmology 2002, 109:838-849.
25. Heindl L.M., Lotter M., Strnad V., et al. High dose (106)Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinic-pathologic study. Ophthalmologe 2007, 104:149-157.
26. Damato B., Patel I., Campbell I., et al. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 2005, 63:385-391.
27. Gunduz K., Shields C.L., Shields J.A., et al. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 1999, 127:579-589.
28. Seregard S., Trampe E., Lax I., et al. Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma, the Swedish experience. Acta Ophthalmol Scand 1997, 75:11-16.
29. Lommatzsch P.K. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 Years' experience. Br J Ophthalmol 1986, 70:844-885.
30. Lommatzsch P.K., Werschnik C., Schuster E. Long-term follow-up for Ru-106 brachytherapy in conservative treatment of uveal melanoma. Arch Clin Exp Ophthalmol Surg 1993, 24:82-90.
31. Nag S., Quivey J.M., Earle J.D., et al. The American brachytherapy society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 2003, 56:544-555.
32. Leonard K.L., Bannon E.A., Mignano J.E., et al. Eye plaque brachytherapy for the treatment of uveal melanoma: The 2010 Tufts Medical Center experience. Int J Radiat Oncol Biol Phys 2010, 78S:S268. (Abstr.).
33. Rivard M.J., Chiu-Tsao S.-T., Finger P.T., et al. Comparison of dose calculation methods for brachytherapy of ocular tumors. Med Phys 2011, 38:306-316.
34. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 1995, 22:209-234.
35. Rivard M.J., Coursey B.M., DeWerd L.A., et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004, 31:633-674.
36. Goodsitt M.M., Carson P.L., Witt S., et al. Real-time B-mode ultrasound quality control test procedures: Report of AAPM Ultrasound Task Group No. 1. Med Phys 1998, 25:1385-1406.
37. Dale R.G., Jones B. The clinical radiobiology of brachytherapy. Br J Radiol 1998, 71:465-483.
38. Zhang H., Martin D., Chiu-Tsao S.-T., et al. A comprehensive dosimetric comparison between 131Cs and 125I brachytherapy sources for COMS eye plaque implant. Brachytherapy 2010, 9:362-372.
39. Melhus C.S., Rivard M.J. COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, and 131Cs. Med Phys 2008, 35:3364-3371.
40. Rivard M.J., Melhus C.S., Sioshansi S., et al. The impact of prescription depth, dose rate, plaque size, and source loading on the central axis using 103Pd, 125I, and 131Cs. Brachytherapy 2008, 7:327-335.